MedTrace Logo

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

NCT00855855 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20830

Last updated 2022-04-25

No results posted yet for this study

Summary

To monitor the occurrence of invasive Hib disease over time and to determine product-specific rates of invasive Hib disease within the monitored population.

Conditions

  • Haemophilus Infections
  • Diphtheria
  • Tetanus
  • Polio
  • Pertussis

Interventions

BIOLOGICAL

DTaP-IPV/Hib

0.5 mL, Intramuscular

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Director · Sanofi Pasteur Inc.

Eligibility

Max Age
59 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00855855 on ClinicalTrials.gov